Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

References

• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011–8
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms: An update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165–80
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 2006; 42: 582–8
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol 1999; 17: 2572–8
   PubMed Web of Science ®Google Scholar
• Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007; 9: 29–38
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003; 62: 297–303
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66: 11520–39
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24–40
   PubMedGoogle Scholar
• Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610–22
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843–8
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769–77
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ Desjardins A Herndon JE 2nd, Dowell JM Reardon DA Quinn JA et al Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ Desjardins A Herndon JE 2nd, Marcello J Reardon DA Quinn JA et al Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Satayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779–87
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn K, Yung WKA, Jaeckle K, Robins HI, Mehta M, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 2006; 8: 189–93
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007; 114: 97–109
   PubMed Web of Science ®Google Scholar
• NCI Common Terminology Criteria for Adverse Events v.3.0 (CTCAE) [published 2006 Aug 8; cited 2008 Sep 15]. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
   Google Scholar
• MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–80
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005; 7: 369: abstr 342
   Google Scholar
• Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 2008; 164: 588–94
   PubMed Web of Science ®Google Scholar
• Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998; 22: 816–26
   PubMed Web of Science ®Google Scholar
• Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, et al. Vascular endothelial growth factor (VEGF) in astrocytic gliomas: a prognostic factor?. J Neurooncol 1999; 45: 117–25
   PubMedGoogle Scholar
• Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43–8
   PubMedGoogle Scholar
• Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, Kotsiakis X, et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007; 295: 75–83
   PubMed Web of Science ®Google Scholar
• Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008; 29: 419–24
   PubMed Web of Science ®Google Scholar
• Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to Bevacizumab and Irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007; 25: 4714–21
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade glioma. J Clin Oncol 2000; 18: 708–15
   PubMed Web of Science ®Google Scholar
• Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 2001; 51: 41–5
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007; 110: 13–24
   PubMed Web of Science ®Google Scholar
• Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004; 67: 191–200
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, et al. A North American brain tumor consortium (NABTC 99–04) phase II trial of temozolamide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007; 81: 271–7
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Gigas DC, Gigas DC, Batchelor TT, Muzikansky A, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007; 9: 354–63
   PubMed Web of Science ®Google Scholar
• Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 15: 2299–2304
   Google Scholar
• Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007; 23: 181–98
   Google Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33(5 Suppl 10)S26–34
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Bernstein M, Resch L, Tator CH, Fleming JF, Vanderlinden RG, et al. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg 1987; 67: 852–7
   PubMed Web of Science ®Google Scholar